Delphine Masschaele
Senior Scientist - Clinical Argenx
Seminars
Wednesday 22nd July 2026
Redefining the Role of Autoantibodies in Myasthenia Gravis to Improve Therapeutic Positioning & Diagnostic Precision
11:00 am
- Biological drivers for variability in clinical response to efgartigimod despite IgG reduction, reflecting heterogeneity in distinct pathogenic mechanisms
- Exploration of disease‑relevant molecular pathways that may not be fully addressed by FcRn inhibition alone, providing a biological rationale for rational combination strategies targeting complementary mechanisms across heterogeneous patient subsets
- Re-examining “seronegativity” in MG as a potential misclassification challenge and whether so-called seronegative MG reflect true absence of pathogenic antibodies or limitations in assay sensitivity and testing paradigms to refine patient diagnosis and avoid biologically inappropriate therapeutic deployment
